Delving into the Latest Updates on Norvancomycin Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

NVCM

Target

Peptidoglycan

Action

inhibitors

Mechanism

Peptidoglycan inhibitors

Therapeutic Areas

Infectious Diseases

Active Indication

Bacterial Infections

Inactive Indication-

Originator Organization

North China Pharmaceutical Huasheng Co., Ltd.

Active Organization

North China Pharmaceutical Huasheng Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1995),

Bacterial Infections

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC65H73Cl2N9O24

InChIKeyNUAQIRUAZSJTAI-YRPZDAAMSA-N

CAS Registry91700-98-0

Vancomycin and norvancomycin have diminished antibacterial efficacy due to acquired or intrinsic resistance from mutations in the terminal dipeptide of lipid II in Gram-positive bacteria or failure to penetrate into the periplasm in Gram-negative bacteria. Herein, we rationally designed and synthesized a series of vancomycin analogues bearing single amine or guanidine functionality, altering various linkers and modification sites, to combat the resistance. Extensive antibacterial screening was performed to delineate a comprehensive SAR. Many derivatives revitalized the activity in vitro, exhibiting a 4-128-fold or 2-16-fold enhancement against the acquired or intrinsic resistance with lower toxicity. Significantly, the optimal compound 4g demonstrated greater pharmacokinetic and pharmacodynamic profiles. Further studies uncovered additional independent and synergistic mechanisms for 4g, including the enhanced membrane activity and augmented inhibition of peptidoglycan biosynthesis via increased lipid II binding, highlighting its potential as a future lead candidate to replenish the glycopeptide antibiotic arsenal.

16 Nov 2024·Critical Reviews in Analytical Chemistry

Macrocyclic Antibiotics as Effective Chiral Selectors in Liquid Chromatography for Enantiomeric Separation of Pharmaceutical Compounds: A Review

Review

Author: Mahmoud, Abdelrahman ; Salman, Basma E. ; El-Sayed, Doaa H. ; Alzarak, Tasneem M. ; Bakr, Hanan H. ; Adel, Shahd E. ; Fouad, Ali

Chiral separation techniques play a crucial role in the pharmaceutical industry, where the enantiomeric purity of drugs can have a significant impact on their efficacy and safety. Macrocyclic antibiotics are highly effective chiral selectors used in various chiral separation techniques, including LC, HPLC, SMB, and TLC, offering reproducible results and a wide range of applications. However, developing robust and efficient immobilization mechanisms for these chiral selectors remains a challenge. This review article focuses on various immobilization approaches, such as immobilization, coating, encapsulation, and photosynthesis, that have been applied to immobilize macrocyclic antibiotics on their support. Commercially available macrocyclic antibiotics for conventional liquid chromatography include Vancomycin, Norvancomycin, Eremomycin, Teicoplanin, Ristocetin A, Rifamycin, Avoparcin, Bacitracin, and others. In addition, capillary (nano) liquid chromatography has also been used in chiral separation utilizing Vancomycin, Polymyxin B, Daptomycin, and Colistin Sulfate. Macrocyclic antibiotic-based CSPs have been extensively applied due to their reproducible results, ease of use, and broad range of applications, capable of separating a large number of racemates.

08 Nov 2024·Medicine

Effectiveness, safety, and cost-effectiveness of norvancomycin in the management of acute hematogenous osteomyelitis in pediatric patients: A retrospective case study

Article

Author: Hu, Ningning ; Zhang, Nan ; Pei, Yuntao ; Zhang, Xueqin ; Zhang, Liming ; Zhao, Yile ; Chen, Xiaohui

This study was designed to investigate the effectiveness, safety, and cost-effectiveness of norvancomycin in the management of acute hematogenous osteomyelitis in pediatric patients. We conducted a retrospective study on cases of osteomyelitis in pediatric patients treated with norvancomycin or vancomycin at Hebei Children’s Hospital from January 2015 to February 2023. The patients were categorized into the norvancomycin group and the vancomycin group. Clinical data regarding efficacy, safety, and cost-effectiveness before and after drug treatment were collected for comparative analysis. Each group contained 104 children. After 14 days of treatment, there were no statistically significant differences in the incidence of adverse events and efficacy indexes between the 2 groups. However, the total hospitalization cost of the norvancomycin group (¥28765.35 ± ¥11835.98) was significantly lower than that of the vancomycin group (¥43776.06 ± ¥33365.30) (P = .000). Additionally, compared to the vancomycin group, both the clinical efficacy cost ratio (290.44 vs 437.76) and bacteriological clearance cost ratio (356.14 vs 576.30) were lower in the norvancomycin group. Norvancomycin demonstrates comparable efficacy to the first-line drug vancomycin in treating acute hematogenous osteomyelitis in pediatric patients. Moreover, norvancomycin can significantly mitigate treatment expenses and exhibit favorable cost-effectiveness.

100 Deals associated with Norvancomycin Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J01	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	China	North China Pharmaceutical Huasheng Co., Ltd.	01 Jan 1995

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2020	Not Applicable	-	-	norvancomycin (Continuous Topical Ocular Instillation Drug Delivery (CTOIDD))	(kgsvyqepri) = oimrzlodna oiywzyoiiu (tzxazxfnti )	-	01 Jun 2020